Global Leukocyte Adhesion Deficiency Management Market Report 2024: Growth Rate, Major Segments And Regions

saikiran TBRC

Global Leukocyte Adhesion Deficiency Management Market Report 2024: Growth Rate, Major Segments And Regions

The Leukocyte Adhesion Deficiency Management Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Leukocyte Adhesion Deficiency Management Market:

https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report

According to The Business Research Company’s Leukocyte Adhesion Deficiency Management Global Market Report 2024, The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements..

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies.. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies..

The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body's immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13172&type=smp

The leukocyte adhesion deficiency management market covered in this report is segmented –

1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors

2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Major companies operating in the leukocyte adhesion deficiency management market are focused on developing novel treatments and therapies, such as RP-L201, to address the underlying genetic defects and improve the quality of life for affected individuals. Regenerative Medicine Advanced Therapy (RMAT) for RP-L201 supports the efficient development of advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, in March 2021, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, received the U.S. Food and Drug Administration (FDA) designation for Regenerative Medicine Advanced Therapy (RMAT) (RP-L201). The RMAT designation was obtained based on promising preliminary safety and efficacy data from RP-L201's ongoing Phase 1/2 clinical trial. The RMAT designation was created to aid in developing and approving regenerative medicine products such as cell and gene therapies. The designation is given to an investigational product that has the potential to treat, alter, reverse, or cure a serious or life-threatening disease or condition and is supported by preliminary clinical evidence demonstrating its ability to address an unmet medical need.

The leukocyte adhesion deficiency management market report table of contents includes:

1. Executive Summary

2.Leukocyte Adhesion Deficiency Management Market Characteristics

3.Leukocyte Adhesion Deficiency Management Market Trends And Strategies

4.Leukocyte Adhesion Deficiency Management Market analysis

5.Leukocyte Adhesion Deficiency Management Market Size And Growth

6.Leukocyte Adhesion Deficiency Management Segmentation

7.Leukocyte Adhesion Deficiency Management Regional And Country Analysis

27.Leukocyte Adhesion Deficiency Management Competitive Landscape And Company Profiles

28.Leukocyte Adhesion Deficiency Management Key Mergers And Acquisitions

29.Leukocyte Adhesion Deficiency Management Future Outlook and Potential Analysis

TOP MAJOR PLAYERS: